HRS-7058 for non-small cell lung cancer after prior treatment
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests an experimental drug for advanced non-small cell lung cancer that has a specific gene change called KRAS G12C. It is for people whose cancer has not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced or metastatic non-small cell lung cancer.
- Your tumor has the KRAS G12C mutation.
- You have already tried at least one standard treatment, including chemo and immunotherapy.
- You have at least one measurable tumor and are generally able to care for yourself.
- Your cancer has not spread to the brain or spinal cord.
- You have not had another cancer in the last 5 years.
- You do not have serious heart, lung, liver, kidney, or bleeding problems.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new pill called Garsorasib for people with advanced non-small cell lung cancer that has a specific gene change called KRAS G12C. It aims to see if the drug can shrink tumors or slow cancer growth in people who haven't had treatment yet.
This trial tests a new drug called HS-10370 combined with other anti-cancer treatments for people with advanced lung cancer that has a specific genetic change (KRAS G12C). The goal is to see if this combination can shrink or control tumors better than other options.
This trial tests a new combination of two targeted medicines for advanced non-small cell lung cancer with a specific gene change (KRAS G12C). The goal is to see if this combination can shrink or slow the cancer.
This Phase 2 trial studies sotorasib, a targeted medicine, in people with non-small cell lung cancer (NSCLC) that has a specific KRAS mutation called G12C. You may be eligible if your cancer has spread or can’t be removed by surgery and has grown again after at least one previous treatment.
This trial tests an oral targeted drug called sotorasib for people with a specific type of advanced lung cancer (KRAS G12C mutation) who have not had any prior treatment for their advanced disease. It aims to see if this drug can shrink tumors and help patients without using standard chemotherapy or immunotherapy first.
This trial tests a new drug, HRS-6093, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and effective for those who have not responded to or cannot tolerate other treatments.
Hear when a new KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.